...
首页> 外文期刊>BMC Infectious Diseases >Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries
【24h】

Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries

机译:估算欧盟​​/欧洲经济区中慢性丙型肝炎病毒感染的规模:以抗丙型肝炎流行国家的移民为重点

获取原文

摘要

Increasing the proportion diagnosed with and on treatment for chronic hepatitis C (CHC) is key to the elimination of hepatitis C in Europe. This study contributes to secondary prevention planning in the European Union/European Economic Area (EU/EEA) by estimating the number of CHC (anti-HCV positive and viraemic) cases among migrants living in the EU/EEA and born in endemic countries, defining the most affected migrant populations, and assessing whether country of birth prevalence is a reliable proxy for migrant prevalence. Migrant country of birth and population size extracted from statistical databases and anti-HCV prevalence in countries of birth and in EU/EEA countries derived from a systematic literature search were used to estimate caseload among and most affected migrants. Reliability of country of birth prevalence as a proxy for migrant prevalence was assessed via a systematic literature search. Approximately 11% of the EU/EEA adult population is foreign-born, 79% of whom were born in endemic (anti-HCV prevalence ≥1%) countries. Anti-HCV/CHC prevalence in migrants from endemic countries residing in the EU/EEA is estimated at 2.3%/1.6%, corresponding to ~580,000 CHC infections or 14% of the CHC disease burden in the EU/EEA. The highest number of cases is found among migrants from Romania and Russia (50–60,000 cases each) and migrants from Italy, Morocco, Pakistan, Poland and Ukraine (25–35,000 cases each). Ten studies reporting prevalence in migrants in Europe were identified; in seven of these estimates, prevalence was comparable with the country of birth prevalence and in three estimates it was lower. Migrants are disproportionately affected by CHC, account for a considerable number of CHC infections in EU/EEA countries, and are an important population for targeted case finding and treatment. Limited data suggest that country of birth prevalence can be used as a proxy for the prevalence in migrants.
机译:在欧洲,增加诊断和治疗慢性丙型肝炎(CHC)的比例是消除丙型肝炎的关键。这项研究通过估算居住在欧盟/欧洲经济区且在流行国家出生的移民中的CHC(抗HCV阳性和病毒感染)病例的数量,为欧盟/欧洲经济区(EU / EEA)的二级预防规划做出了贡献,受影响最严重的移民人口,并评估出生率国家是否是移民流行率的可靠代表。从统计数据库中提取的移民出生国和人口规模,以及通过系统的文献检索得出的出生国和欧盟/欧洲经济区国家中的抗丙型肝炎流行率,可用来估计受影响最大的移民中的病例数。通过系统的文献检索,评估了出生率高的国家作为移民流行率的代表的可靠性。欧盟/欧洲经济区成年人口中约有11%是外国出生的,其中79%出生于地方性(抗HCV流行率≥1%)国家。来自居住在EU / EEA的流行国家的移民中的抗HCV / CHC流行率估计为2.3%/ 1.6%,相当于〜580,000 CHC感染或EU / EEA中CHC疾病负担的14%。病例最多的是罗马尼亚和俄罗斯移民(每人50-60,000例)和意大利,摩洛哥,巴基斯坦,波兰和乌克兰的移民(每人25-35,000例)。确定了十项报告欧洲移民流行情况的研究;在这些估计数中的七个中,患病率与出生率国家相当,而在三个估计中则较低。移民受到CHC的影响不成比例,在EU / EEA国家中占相当数量的CHC感染,并且是有针对性病例发现和治疗的重要人群。有限的数据表明,出生率高的国家可以用来代替移民的流行率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号